H. Lundbeck A/S (OTCMKTS:HLUYY – Get Rating) – Equities researchers at SVB Leerink upped their Q1 2022 EPS estimates for H. Lundbeck A/S in a research note issued on Thursday, April 21st. SVB Leerink analyst M. Goodman now forecasts that the company will earn $0.58 per share for the quarter, up from their previous estimate of $0.51. SVB Leerink also issued estimates for H. Lundbeck A/S’s Q2 2022 earnings at $0.67 EPS, Q3 2022 earnings at $0.58 EPS and Q4 2022 earnings at $0.33 EPS.
Other equities research analysts also recently issued reports about the company. Barclays reduced their target price on H. Lundbeck A/S from 200.00 to 190.00 in a report on Tuesday, February 22nd. JPMorgan Chase & Co. dropped their price target on H. Lundbeck A/S from 250.00 to 200.00 in a research report on Tuesday, January 4th. Credit Suisse Group dropped their price target on H. Lundbeck A/S from 175.00 to 163.00 in a research report on Thursday, February 10th. Finally, Zacks Investment Research raised H. Lundbeck A/S from a “sell” rating to a “hold” rating in a research report on Tuesday, April 12th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, H. Lundbeck A/S has an average rating of “Hold” and an average target price of $122.93.
The firm also recently declared a dividend, which was paid on Tuesday, April 5th. Investors of record on Friday, March 25th were given a dividend of $0.2044 per share. This represents a yield of 0.85%. The ex-dividend date of this dividend was Thursday, March 24th. H. Lundbeck A/S’s payout ratio is 12.20%.
H. Lundbeck A/S Company Profile (Get Rating)
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia.
- Get a free copy of the StockNews.com research report on H. Lundbeck A/S (HLUYY)
- MarketBeat: Week in Review 4/18 – 4/22
- Tractor Supply Company Reaps What It Sows
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- Should You Buy Carvana or AutoNation or Pass on Both?
- MarketBeat Podcast: 3 Stocks Flashing Buy Signals
Receive News & Ratings for H. Lundbeck A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. Lundbeck A/S and related companies with MarketBeat.com's FREE daily email newsletter.